Literature DB >> 10711551

Direct medical cost of pelvic inflammatory disease and its sequelae: decreasing, but still substantial.

D B Rein1, W J Kassler, K L Irwin, L Rabiee.   

Abstract

OBJECTIVE: To estimate direct medical costs and average lifetime cost per case of pelvic inflammatory disease (PID).
METHODS: We estimated the direct medical expenditures for PID and its three major sequelae (chronic pelvic pain, ectopic pregnancy, and infertility) and determined the average lifetime cost of a case of PID and its sequelae. We analyzed 3 years of claims data of privately insured individuals to determine costs, and 3 years of national survey data to determine number of cases of PID, chronic pelvic pain, and ectopic pregnancy. We developed a probability model to determine the average lifetime cost of a case of PID.
RESULTS: Direct medical expenditures for PID and its sequelae were estimated at $1.88 billion in 1998: $1.06 billion for PID, $166 million for chronic pelvic pain, $295 million for ectopic pregnancy, and $360 million for infertility associated with PID. The expected lifetime cost of a case of PID was $1167 in 1998 dollars. The majority of those costs ($843 per case) represent care for acute PID rather than diagnosis and treatment of sequelae. Approximately 73% of cases will not accrue costs beyond the treatment of acute PID.
CONCLUSION: The direct medical cost of PID is still substantial. The majority of PID related costs are incurred in the treatment of acute PID. Because most PID-related costs arise in the first year from treatment of acute PID infection, strategies that prevent PID are likely to be cost-effective within a single year.

Entities:  

Mesh:

Year:  2000        PMID: 10711551     DOI: 10.1016/s0029-7844(99)00551-7

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  36 in total

1.  Performance of the MagNA pure LC robot for extraction of Chlamydia trachomatis and Neisseria gonorrhoeae DNA from urine and swab specimens.

Authors:  Nicholas Dalesio; Vince Marsiglia; Andrew Quinn; Thomas C Quinn; Charlotte A Gaydos
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

2.  Pelvic Inflammatory Disease: Current Concepts of Diagnosis and Management.

Authors:  Richard L Sweet
Journal:  Curr Infect Dis Rep       Date:  2012-02-02       Impact factor: 3.725

3.  Sexual behaviour: related adverse health burden in the United States.

Authors:  S H Ebrahim; M T McKenna; J S Marks
Journal:  Sex Transm Infect       Date:  2005-02       Impact factor: 3.519

Review 4.  Cost-of-illness studies : a review of current methods.

Authors:  Ebere Akobundu; Jing Ju; Lisa Blatt; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

5.  Diagnosing Vaginal Infections: It's Time to Join the 21st Century.

Authors:  Barbara Van Der Pol
Journal:  Curr Infect Dis Rep       Date:  2010-05       Impact factor: 3.725

Review 6.  Status of adolescent pelvic inflammatory disease management in the United States.

Authors:  Maria Trent
Journal:  Curr Opin Obstet Gynecol       Date:  2013-10       Impact factor: 1.927

7.  Estimating the direct costs of pelvic inflammatory disease in adolescents: a within-system analysis.

Authors:  Maria Trent; Jonathan M Ellen; Kevin D Frick
Journal:  Sex Transm Dis       Date:  2011-04       Impact factor: 2.830

8.  Improving sexually transmitted infection results notification via mobile phone technology.

Authors:  Jennifer L Reed; Jill S Huppert; Regina G Taylor; Gordon L Gillespie; Terri L Byczkowski; Jessica A Kahn; Evaline A Alessandrini
Journal:  J Adolesc Health       Date:  2014-06-21       Impact factor: 5.012

9.  Do short-term markers of treatment efficacy predict long-term sequelae of pelvic inflammatory disease?

Authors:  Gail M Trautmann; Kevin E Kip; Holly E Richter; David E Soper; Jeffrey F Peipert; Deborah B Nelson; Wayne Trout; Dianne Schubeck; Debra C Bass; Roberta B Ness
Journal:  Am J Obstet Gynecol       Date:  2008-01       Impact factor: 8.661

10.  Cost-effectiveness of universal screening for chlamydia and gonorrhea in US jails.

Authors:  Julie R Kraut-Becher; Thomas L Gift; Anne C Haddix; Kathleen L Irwin; Robert B Greifinger
Journal:  J Urban Health       Date:  2004-09       Impact factor: 3.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.